Channels - Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Similar Items: Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Quick Look
Characterizing Adherence to a Mobile Health App for Patient-Reported Outcomes in Rheumatoid Arthritis
Quick Look
The association between bariatric surgery and incident rheumatoid arthritis
Quick Look
Mycobacterium Intracellulare Infection of the Metacarpophalangeal Joint in a Patient With Rheumatoid Arthritis: A Case Report
Quick Look
Biologic Therapy Is Associated with Faster Bone Union After the Sauvé–Kapandji Procedure in Patients with Rheumatoid Arthritis
Quick Look
Herpes Zoster Risk in Rheumatoid Arthritis Patients on Janus Kinase Inhibitors: A 17-Year Experience from Rheumatoid Arthritis Saudi Database (RASD)
Quick Look
Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination?
Quick Look
The prevalence of interstitial lung disease in rheumatoid arthritis: a systematic review
Quick Look
Correction to “Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders”
Quick Look
Genital Tuberculosis and Serous Cystadenoma in a 58-Year-Old Female With Rheumatoid Arthritis and Sjögren’s Syndrome: A Case Report
Quick Look
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
Quick Look
Exploring Antifibrotic Strategies for Interstitial Lung Disease in Rheumatoid Arthritis: A Narrative Review
Quick Look
Hepatic fibrosis in patients diagnosed with rheumatoid arthritis and psoriatic arthritis receiving methotrexate: A cross‐sectional analysis using transient elastography
Quick Look
Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies
Quick Look
Variation in the feasibility and acceptability of electronic patient-reported outcome measures in patients with inflammatory arthritis
Quick Look
Prevalence and Predictors of Osteoporosis Among Saudi Patients with Rheumatoid Arthritis: A Single-Center Cross-Sectional Study
Quick Look
Clinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey
Quick Look
The prevalence of pulmonary airway lesions is high in HTLV-1-positive rheumatoid arthritis: a cross-sectional observational study
Quick Look
Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study
Quick Look
Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting
Quick Look
Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence
Quick Look
Corrigendum “Exposure to arboviral infections and risk of rheumatoid arthritis: Findings from the MyEIRA population‐based case‐control study”
Quick Look
Treatment Patterns and Outcomes of Acthar Gel in Ankylosing Spondylitis and Psoriatic Arthritis: A Physician-Reported Chart Review
Quick Look
Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort
Quick Look
A Cross-Sectional Study of the Relationship Between Disease Activity and Fatigue in Rheumatoid Arthritis Patients at King Abdulaziz University Hospital, Saudi Arabia